Supplementary Table 6.
Distribution of main demographic and clinical data in the entire group of anti-HBc positive hemodialysis patients selected according to genotypes of MCP1 rs1024611.
| Parameter | AA n=87 |
AG n=66 |
GG n=17 |
P value between all groups |
|---|---|---|---|---|
| Male gender (n,%) | 53 (60.9) | 34 (51.5) | 12 (70.6) | 0.290a |
| Age (years) | 61.1±14.7 | 62.7±14.3 | 61.4±16.8 | 0.979b |
| Diabetic nephropathy (n,%) | 21 (24.1) | 22 (33.3) | 5 (29.4) | 0.462a |
| Chronic glomerulonephritis (n,%) | 16 (18.4) | 12 (18.2) | 4 (23.5) | 0.917a |
| Hypertensive nephropathy (n,%) | 18 (20.7) | 8 (12.1) | 0 (0.0) | 0.066c |
| Chronic tubulointerstitial nephritis (n,%) | 5 (5.7) | 5 (7.6) | 3 (17.6) | 0.237a |
| Polycystic kidney disease (n,%) | 4 (4.6) | 4 (6.1) | 0 (0.0) | 0.766c |
| RRT vintage (years) | 2.5 (0.05–25.1) | 3.6 (0.05–26.3) | 2.3 (0.14–24.8) | 0.512d |
| HBsAg positive/anti-HBs negative (n,%) | 4 (4.6) | 7 (10.6) | 4 (23.5) |
0.028a AA vs. AG p=0.268e AA vs. GG p=0.029e AG vs. GG p=0.317e |
| HBsAg negative/anti-HBs positive (n,%) | 66 (75.9) | 48 (72.7) | 12 (70.6) | 0.844a |
| Isolated anti-HBc positivity (n,%) | 16 (18.4) | 11 (16.7) | 1 (5.9) | 0.472a |
| HBsAg positive/anti-HBs positive (n,%) | 1 (1.1) | 0 (0.0) | 0 (0.0) | 1.000c |
| ALT (U/L) | 17 (3–50) | 15 (2–195) | 19 (9–95) | 0.266d |
| AST (U/L) | 16 (6–72) | 19 (9–152) | 18 (9–64) | 0.571d |
| GGT (U/L) | 25 (4–498) | 27 (5–211) | 35 (10–147) | 0.757d |
ALT – alanine aminotransferase; anti-HBc – antibodies to core antigen of hepatitis B virus; anti-HBs – antibodies to surface antigen of hepatitis B virus; AST – aspartate aminotransferase; GGT – gamma-glutamyltranspeptidase; HBsAg – surface antigen of hepatitis B virus; RRT – renal replacement therapy. Statistical tests:
a
– Chi square;
b
– ANOVA;
c
– Fisher Freeman Halton;
d
– Kruskal-Wallis;
e
– Yates corrected Chi-square.
Significant differences are indicated using bold font.